1. INTRODUCTION
===============

In Canada, breast cancer is the most common malignancy in women. During the last 15 years, an estimated 162,600 Canadian women were diagnosed with breast cancer, with more than 22,000 new cases diagnosed annually[@b1-co15_s1p016]. Following surgery, nearly all affected women will receive some form of adjuvant systemic therapy---cytotoxic chemotherapy, endocrine therapy, targeted therapy with a monoclonal antibody, or a combination---to reduce their risk of relapse and to improve survival. As a result of this improved adjuvant therapy and earlier detection with mammographic screening, the age-adjusted mortality of early-stage breast cancer continues to decline, with 96% and 86% of stage [i]{.smallcaps} and [ii]{.smallcaps} patients respectively expected to survive more than 5 years from initial diagnosis[@b1-co15_s1p016].

Given a burgeoning population of long-term breast cancer survivors and an increasing recognition that breast cancer is a molecularly heterogeneous disease in which only subgroups of patients may benefit from specific adjuvant therapies[@b2-co15_s1p016]--[@b6-co15_s1p016], minimizing the long-term side effects of treatment is now of utmost significance. Cardiac toxicity, which is among the most dreaded of the long-term complications of cancer treatment, has been reported with all three forms of adjuvant systemic therapy for breast cancer. The present article reviews the current understanding of cardiac toxicity risk and strategies to minimize cardiac morbidity associated with cytotoxic chemotherapy, trastuzumab therapy, and hormonal therapy with aromatase inhibitors ([ai]{.smallcaps}s) for early-stage breast cancer.

2. ANTHRACYCLINE-INDUCED CARDIOTOXICITY
=======================================

The anthracycline class of chemotherapeutic agents is commonly used to treat a variety of malignancies, including breast, gastric, and esophageal cancers, and sarcoma, lymphoma, and leukemia. A large meta-analysis of early clinical trials in breast cancer established the superiority of anthracycline-based adjuvant chemotherapy over the traditional cyclophosphamide, methotrexate, and 5-fluorouracil ([cmf]{.smallcaps}) regimen with an absolute 4% improvement in overall survival at 10 years[@b7-co15_s1p016]. Following the introduction of anthracyclines, more recent clinical trials have tried to define the optimal type, dose, and schedule of anthracycline administration; the value of adding agents such as taxanes and targeted therapies to an anthracycline backbone; and the possible alternatives to anthracycline-based therapy[@b8-co15_s1p016],[@b9-co15_s1p016].

Starting with their initial use in the 1960s, anthracyclines were recognized to potentially cause a variety of cardiac side effects. Rare acute toxicities include supraventricular tachycardia, electrocardiographic changes, ventricular ectopy, myopericarditis, and sudden death[@b10-co15_s1p016]. A serious long-term side effect of anthracycline therapy is the development of a dilated cardiomyopathy highlighted by systolic dysfunction and left-sided congestive heart failure[@b11-co15_s1p016], which usually occurs 2--5 years after the last anthracycline dose. Late anthracycline-induced cardiomyopathy can develop insidiously, without significant evidence of systolic dysfunction on traditional measures of left ventricular ejection fraction ([lvef]{.smallcaps})[@b12-co15_s1p016] such as multiple gated acquisition scans or two-dimensional echocardiography. After the onset of symptoms of congestive heart failure ([chf]{.smallcaps}) secondary to anthracycline-induced cardiomyopathy, outcome is quite poor, with a median survival of approximately 1 year in a large population-based series[@b13-co15_s1p016].

2.1 Pathogenesis
----------------

The pathophysiology of anthracycline-induced cardiomyopathy is poorly understood. Myocardial cells demonstrate a limited capacity to regenerate, and they are particularly susceptible to the degenerative effects of cytotoxic chemotherapy. Endomyocardial biopsies from patients with anthracycline-induced cardiomyopathy demonstrate irreversible myofibril loss, necrosis, and vacuolar degeneration[@b14-co15_s1p016]. Although numerous mechanisms have been proposed to account for these morphologic features, most studies suggest that anthracyclines cause myocardial damage through oxidative stress[@b15-co15_s1p016]. Anthracyclines form complexes with intracellular iron, leading to the generation of free radical species, lipid peroxidation, and depletion of antioxidants. These events leave myocardial cells susceptible to oxidative injury affecting nucleic acids, intracellular proteins, and mitochondria, which accumulate damage and ultimately trigger cell death.

2.2 Risk Factors for Anthracycline-Induced Cardiomyopathy
---------------------------------------------------------

A number of risk factors are associated with the development of anthracycline-induced cardiomyopathy. A landmark retrospective review by Von Hoff *et al.*[@b16-co15_s1p016] established a clear relationship between the cumulative dose of doxorubicin and the risk of [chf]{.smallcaps}. In their series, the incidence of [chf]{.smallcaps} after 400 mg/m^2^ of doxorubicin was 3%, rising to 7% at 550 mg/m^2^ and 18% at 700 mg/m^2^. Other traditional risk factors associated with anthracycline-induced cardiomyopathy include age greater than 70 years[@b16-co15_s1p016],[@b17-co15_s1p016], mediastinal radiation (concurrent or sequential)[@b17-co15_s1p016]--[@b21-co15_s1p016], pre-existing cardiac disease[@b17-co15_s1p016],[@b20-co15_s1p016], hypertension[@b17-co15_s1p016],[@b19-co15_s1p016], and liver disease[@b22-co15_s1p016]. For reasons that are poorly understood, women are more susceptible to anthracycline-induced cardiomyopathy: as compared with men, they have a lower cumulative-dose threshold[@b23-co15_s1p016].

2.3 Incidence of Anthracycline-Induced Cardiomyopathy
-----------------------------------------------------

Because most multi-agent adjuvant breast cancer chemotherapy regimens deliver a cumulative dose of doxorubicin below 450 mg/m^2^, the risk of cardiac toxicity with anthracycline-based therapy was initially felt to be low. The early adjuvant trials of anthracyclines in breast cancer supported this notion of cardiac safety. In a meta-analysis by the Early Breast Cancer Trialists' Collaborative Group, the mortality from heart disease was 0.08% annually in the anthracycline-treated group as compared with 0.06% annually in the non-anthracycline [cmf]{.smallcaps} group[@b7-co15_s1p016]. A retrospective analysis from a single centre reported a 1% incidence of [chf]{.smallcaps} at a median follow-up of 14 years in a group treated with doxorubicin--[cmf]{.smallcaps}; no [chf]{.smallcaps} events were reported in the [cmf]{.smallcaps}-only group[@b24-co15_s1p016]. However, these early reports included only relatively young patients with few medical comorbidities; they suffered from incomplete reporting and lacked prospective serial cardiac assessment.

More recent population-based studies suggest that the cardiac sequelae from anthracycline-based treatment may be much higher than previously thought. In a review of 31,748 women over the age of 65 years diagnosed with early-stage breast cancer in the Surveillance Epidemiology and End Results ([seer]{.smallcaps})--Medicare database from 1992 to 1999, women who received doxorubicin-based adjuvant chemotherapy were 2.5 times more likely to be diagnosed with cardiomyopathy than were women who did not receive chemotherapy[@b25-co15_s1p016]. This increased risk of cardiomyopathy in the doxorubicin-treated group was observed despite a lower prevalence of pre-existing heart disease in the doxorubicin group before initiation of therapy. Similarly, a separate analysis of the [seer]{.smallcaps} database reported a 38.4% rate of [chf]{.smallcaps} at 10 years in anthracycline-treated women aged 66--70 years as compared with rates of 32.5% and 28% in women of the same age group who received non-anthracycline chemotherapy and no adjuvant chemotherapy respectively[@b26-co15_s1p016],[@b27-co15_s1p016].

Beyond clinically overt [chf]{.smallcaps}, anthracycline-based adjuvant therapy is also associated with subclinical cardiomyopathy. Longer follow-up of early adjuvant anthracycline-based clinical trials has demonstrated that administration of "safe" cumulative doses of doxorubicin below 450 mg/m^2^ may predispose to asymptomatic systolic dysfunction, regarded as a reduction of 10% or more from baseline in [lvef]{.smallcaps}. In the National Cancer Institute of Canada [ma]{.smallcaps}.5 trial, which randomized women with node-positive breast to 6 cycles of a cyclophosphamide, epirubicin, and 5-fluorouracil ([cef]{.smallcaps}) regimen or to 6 cycles of [cmf]{.smallcaps}, 25% of women who received [cef]{.smallcaps} developed an asymptomatic decline of 10% or more in [lvef]{.smallcaps} after 5 years; in the [cmf]{.smallcaps} group, just 9% developed an equivalent decline[@b28-co15_s1p016]. Similarly, the North Central Cancer Treatment Group ([ncctg]{.smallcaps}) N9831 Intergroup Adjuvant Trial, which used doxorubicin and cyclophosphamide ([ac]{.smallcaps}) followed by paclitaxel ([t]{.smallcaps}) as a backbone for the addition of trastuzumab therapy in women with human epidermal growth factor receptor type-2 ([her]{.smallcaps}2) overexpression, reported that 23.4% of patients experienced a 10% or greater decline in [lvef]{.smallcaps} following 4 cycles of [ac]{.smallcaps}[@b29-co15_s1p016]. The long-term clinical impact of this form of subclinical cardiomyopathy is unclear. However, an asymptomatic decline in [lvef]{.smallcaps} may limit the use of further systemic therapies that are potentially cardiotoxic. For example, in the N9831 trial, 7.5% of women would not have been eligible to receive trastuzumab with paclitaxel following 4 cycles of [ac]{.smallcaps} because of a decline in [lvef]{.smallcaps} from baseline[@b30-co15_s1p016].

2.4 Strategies to Reduce Anthracycline-Induced Cardiomyopathy
-------------------------------------------------------------

The success of trastuzumab has rekindled enthusiasm for developing strategies to minimize anthracycline-induced cardiac dysfunction ([Table I](#tI-co15_s1p016){ref-type="table"}). Substituting epirubicin for doxorubicin reduces the incidence of clinical heart failure in the metastatic setting[@b31-co15_s1p016]. Prolonged infusion time and weekly administration of doxorubicin also cause less cardiotoxicity than the standard every-three-weeks bolus administration that is routinely used in clinical practice[@b32-co15_s1p016], but the frequency of hospital visits for weekly administration and the shortage of resources for prolonged infusions make these options unappealing for patients and providers alike. Liposomal formulations of anthracyclines and the use of adjunctive scavengers of free radicals such as dexrazoxane have also been shown to reduce the incidence of [chf]{.smallcaps} in the treatment of metastatic disease[@b33-co15_s1p016]--[@b35-co15_s1p016]. However, no prospective clinical trials are currently evaluating these agents in the adjuvant setting. Beta-blockers[@b36-co15_s1p016] and angiotensin converting-enzyme inhibitors[@b37-co15_s1p016] used in combination with anthracyclines have also demonstrated promise; however, the single-centre studies of these combinations have involved small numbers of patients receiving a variety of chemotherapy combinations with limited long-term follow-up.

To be able to determine which patients should be targeted with cardioprotective strategies in future clinical trials, predictive markers of anthracycline-induced cardiac injury are needed. In a pooled analysis of three trials with serial monitoring of left ventricular function, more than one third of patients who went on to develop [chf]{.smallcaps} secondary to doxorubicin did not demonstrate a greater than 30% reduction in [lvef]{.smallcaps} before the onset of symptoms[@b12-co15_s1p016]. Monitoring of [lvef]{.smallcaps} is clearly an imprecise surveillance tool; it cannot reliably predict which patients with asymptomatic [lvef]{.smallcaps} decline are at risk of future cardiac events. Moreover, significant [chf]{.smallcaps} can occur without a preceding decline in [lvef]{.smallcaps}.

There is hope that alternative techniques of myocardial imaging may provide better discriminative power. In many other forms of cardiomyopathy, systolic dysfunction precedes a diastolic dysfunction. Indices of early diastolic dysfunction detectable by angiocardiography may predict anthracycline-induced cardiotoxicity more reliably than traditional multiple gated acquisition monitoring does[@b38-co15_s1p016]. Biochemical monitoring with troponin[@b39-co15_s1p016]--[@b43-co15_s1p016] or B-type natriuretic peptide[@b44-co15_s1p016] as early markers of anthracycline-induced myocardial injury may also eventually play a role.

Perhaps the most effective strategy for reducing the risk of cardiotoxicity is to limit anthracycline administration to the patients most likely to benefit from adjuvant anthracycline therapy. A recent U.S. Oncology Group trial demonstrated improved disease-free survival ([dfs]{.smallcaps}) for early-stage breast cancer treated with docetaxel and cyclophosphamide ([tc]{.smallcaps}) over standard [ac]{.smallcaps}[@b45-co15_s1p016]. As a result, it may be appropriate to use [tc]{.smallcaps} for early-stage breast cancer patients with a lower risk of cancer recurrence and risk factors for anthracycline cardiotoxicity. For patients with an elevated risk of breast cancer recurrence, in whom clinicians would be inclined to use an anthracycline followed by a taxane, it may be possible to use molecular markers such as co-amplification of topoisomerase [ii]{.smallcaps}α (*TOP2A*) and [her]{.smallcaps}2 as predictors of benefit from adjuvant anthracycline-based therapy[@b46-co15_s1p016]--[@b50-co15_s1p016]. However, the hypothesis that co-amplification of *TOP2A* and [her]{.smallcaps}2 predicts anthracycline sensitivity has yet to be prospectively validated in a clinical trial.

In the future, technology base on gene expression may provide valuable insights into which molecular subsets of breast cancer benefit from adjuvant chemotherapy and therefore warrant the risk of long-term toxicity. However, until prospective clinical trials establish effective alternatives to anthracyclines for patients with an elevated recurrence risk, more research is needed to define risk factors, predictive markers, and effective preventive strategies to minimize the burden of anthracycline-induced cardiotoxicity.

3. TRASTUZUMAB
==============

Approximately 20% of breast cancers amplify or overexpress [her]{.smallcaps}2[@b51-co15_s1p016] (sometimes both). Amplification or overexpression of [her]{.smallcaps}2 is associated with an aggressive breast cancer phenotype[@b52-co15_s1p016]. Tumours with [her]{.smallcaps}2 amplification or overexpression are more likely to demonstrate poor differentiation, high nuclear grade, and high proliferative rates. They are also associated with an increased risk of lymph-node metastasis and decreased estrogen and progesterone receptor expression[@b53-co15_s1p016]. These observations led to the development of trastuzumab (Herceptin: Genentech, San Francisco, CA, U.S.A.), a humanized monoclonal antibody against [her]{.smallcaps}2.

In 2001, a pivotal clinical trial by Slamon *et al.*[@b54-co15_s1p016], which involved 469 patients with previously untreated [her]{.smallcaps}2-positive metastatic breast cancer, randomized patients to chemotherapy alone versus chemotherapy with trastuzumab. As compared with the chemotherapy-alone group, the chemotherapy-plus-trastuzumab group experienced increased time to disease progression (7.4 months vs. 4.6 months, *p* \< 0.001) and an increased response rate (50% vs. 32%; *p* \< 0.001)[@b54-co15_s1p016]. Similar results were seen when trastuzumab was studied in combination with docetaxel[@b55-co15_s1p016]. These encouraging results prompted study of trastuzumab in the adjuvant setting.

To date, five phase [iii]{.smallcaps} trials have studied trastuzumab in early-stage breast cancer: the [ncctg]{.smallcaps} Intergroup trial N9831, the National Surgical Adjuvant Breast and Bowel Project ([nsabp]{.smallcaps}) trial B-31 (which led to a combined analysis with [ncctg]{.smallcaps} N9831), the Herceptin Adjuvant ([hera]{.smallcaps}) trial, the Breast Cancer International Research Group ([bcirg]{.smallcaps}) trial 006, and the Finland Herceptin (Fin[her]{.smallcaps}) trial.

3.1 Adjuvant Trastuzumab Trials for Early-Stage Breast Cancer
-------------------------------------------------------------

The [ncctg]{.smallcaps} N9831, [hera]{.smallcaps}, [bcirg]{.smallcaps} 006, and Fin[her]{.smallcaps} trials evaluated the addition of trastuzumab to adjuvant chemotherapy for node-positive or high-risk node-negative [her]{.smallcaps}2-positive breast cancer; [nsabp]{.smallcaps} B-31 enrolled only node-positive patients ([Table II](#tII-co15_s1p016){ref-type="table"})[@b56-co15_s1p016]--[@b60-co15_s1p016]. The most notable design differences across these trials involved sequential versus concurrent use of trastuzumab with adjuvant chemotherapy, and the administration of anthracyclines.

The [nsabp]{.smallcaps} B-31 trial evaluated concurrent use of trastuzumab with adjuvant chemotherapy. The [ncctg]{.smallcaps} N9831 trial involved two groups with regimens similar to those in the [nsabp]{.smallcaps} B-31 trial, but it also involved a third group that received sequential trastuzumab following adjuvant chemotherapy. This last group was not included in the joint analysis of these two trials, but its preliminary results provided insight on the relative efficacy of trastuzumab when used concurrently with, or sequentially after, the administration of adjuvant chemotherapy.

The [hera]{.smallcaps} trial provided data applicable to a wide range of chemotherapeutic regimens. In that study, 94% of participants received anthracyclines, and 26% received both anthracyclines and taxanes before randomization[@b56-co15_s1p016]. The [hera]{.smallcaps} trial will also provide data on duration of trastuzumab and whether 2 years of treatment with trastuzumab is more beneficial than 1 year of treatment.

The [bcirg]{.smallcaps} 006 trial had a third arm (a combination of docetaxel, carboplatin, and trastuzumab) that did not contain an anthracycline, providing information on whether trastuzumab is effective with non-anthracycline-based chemotherapy.

The Fin[her]{.smallcaps} trial randomly assigned 1010 patients to docetaxel or vinorelbine followed by 5-fluorouracil, epirubicin, and cyclophosphamide for 3 cycles. The 232 [her]{.smallcaps}2-positive patients from this study were further randomized to trastuzumab or observation, and trastuzumab was given concurrently over 9 weeks with either docetaxel or vinorelbine.

The primary endpoint of all of the foregoing studies was either [dfs]{.smallcaps} or recurrence-free survival[@b56-co15_s1p016]--[@b60-co15_s1p016]. The secondary endpoints included overall survival and time to distant recurrence[@b56-co15_s1p016]--[@b60-co15_s1p016]. All of these trials have now reported an approximate 50% reduction in the risk of recurrence for patients assigned to receive adjuvant trastuzumab ([Table II](#tII-co15_s1p016){ref-type="table"}) [@b56-co15_s1p016]--[@b60-co15_s1p016].

3.2 Trastuzumab-Induced Cardiotoxicity
--------------------------------------

Early clinical trials with trastuzumab in patients with metastatic disease did not prospectively monitor for cardiac toxicity[@b51-co15_s1p016],[@b62-co15_s1p016]. However, the independent Cardiac Review and Evaluation Committee ([crec]{.smallcaps}) retrospectively reviewed patients enrolled in seven phase [ii]{.smallcaps} and [iii]{.smallcaps} trials to evaluate the risk of cardiac dysfunction associated with trastuzumab[@b63-co15_s1p016]. The [ac]{.smallcaps} combination with trastuzumab had the highest rates of cardiotoxicity with a 27% incidence of cardiac dysfunction, including a 16% incidence of New York Heart Association ([nyha]{.smallcaps}) class [iii]{.smallcaps}/[iv]{.smallcaps} heart failure[@b63-co15_s1p016]. In comparison, cardiac dysfunction developed in 13% of patients treated with paclitaxel and trastuzumab (including 2% [nyha]{.smallcaps} class [iii]{.smallcaps} and [iv chf]{.smallcaps}) and in 3%--7% of patients treated with trastuzumab alone[@b63-co15_s1p016]. The [crec]{.smallcaps} concluded that, given the 25% improvement in overall survival associated with the use of trastuzumab in metastatic disease[@b55-co15_s1p016], the benefits of trastuzumab in patients with [her]{.smallcaps}2-positive breast cancer outweighed the risk of cardiac dysfunction[@b63-co15_s1p016]. Also, based on the high rates of cardiac dysfunction noted in relevant populations, anthracyclines and trastuzumab should no longer be used concurrently in clinical practice. The observations by the [crec]{.smallcaps} led to the development of strict inclusion and exclusion criteria and guidelines for prospective cardiac monitoring in adjuvant trials.

### 3.2.1 Cardiac Eligibility Criteria and Cardiac Monitoring

Most of the adjuvant trastuzumab trials had cardiac eligibility criteria that required a [lvef]{.smallcaps} of more than 50% and that excluded patients with a history of cardiac disease or cardiac risk factors ([Table III](#tIII-co15_s1p016){ref-type="table"})[@b56-co15_s1p016],[@b58-co15_s1p016],[@b59-co15_s1p016],[@b61-co15_s1p016],[@b64-co15_s1p016]. The [hera]{.smallcaps} trial was the exception, using a [lvef]{.smallcaps} cut-off of more than 55%. In the combined analysis of [nsabp]{.smallcaps} B-31 and [ncctg]{.smallcaps} N9831, patients were excluded from trastuzumab initiation if their [lvef]{.smallcaps} after anthracycline therapy was below the lower limit of normal or had declined by more than 15% from baseline, or if clinically significant cardiac symptoms had developed after treatment with anthracyclines[@b64-co15_s1p016]. Based on those criteria, 233 of 3497 patients (6.7%) who had completed doxorubicin and cyclophosphamide therapy were not able to initiate trastuzumab therapy[@b64-co15_s1p016]. Similarly, in the [bcirg]{.smallcaps} trial, approximately 2.4% of patients did not go on to receive trastuzumab after anthracycline therapy[@b61-co15_s1p016].

The adjuvant trials also rigorously monitored [lvef]{.smallcaps} at baseline and throughout the study period, including after anthracycline administration. The [hera]{.smallcaps} trial has the longest prospective [lvef]{.smallcaps} follow-up of the adjuvant trials to date, with a final [lvef]{.smallcaps} assessment at 60 months after randomization[@b56-co15_s1p016].

### 3.2.2 Definition of Cardiac Toxicity and Criteria to Discontinue Trastuzumab

Although all five adjuvant trials evaluated cardiac dysfunction, their definitions of cardiac events and their guidelines for discontinuation or reintroduction of trastuzumab after documentation of a cardiac event showed subtle differences ([Table III](#tIII-co15_s1p016){ref-type="table"}) [@b56-co15_s1p016],[@b58-co15_s1p016],[@b59-co15_s1p016],[@b61-co15_s1p016],[@b64-co15_s1p016]. All five trials defined cardiac death and symptomatic heart failure as cardiac endpoints. However, they used variable definitions for significant [lvef]{.smallcaps} declines from baseline and absolute [lvef]{.smallcaps} cut-offs ([Table III](#tIII-co15_s1p016){ref-type="table"})[@b56-co15_s1p016],[@b58-co15_s1p016],[@b59-co15_s1p016],[@b61-co15_s1p016],[@b64-co15_s1p016]. The [nsabp]{.smallcaps} B-31 and [ncctg]{.smallcaps} N9831 trials defined cardiac endpoints as cardiac death or symptomatic heart failure ([nyha iii]{.smallcaps}/[iv]{.smallcaps}), confirmed by a cardiac review panel[@b30-co15_s1p016]; on the other hand, the [hera]{.smallcaps} trial used cardiac death or symptomatic heart failure ([nyha iii]{.smallcaps}/[iv]{.smallcaps}) with a drop in [lvef]{.smallcaps} of at least 10% from baseline and below an absolute value of 50%[@b56-co15_s1p016]. These differences across the trials make direct comparison of their results difficult. The [hera]{.smallcaps}, [bcirg]{.smallcaps}, and Fin[her]{.smallcaps} trials also included asymptomatic declines in [lvef]{.smallcaps} as a cardiac endpoint, again using different [lvef]{.smallcaps} cut-offs in their definitions. The [bcirg]{.smallcaps} trial differed in that it also included grade 3 or 4 ischemia or infarction and grade 3 or 4 arrhythmia as cardiac endpoints[@b61-co15_s1p016]. The Fin[her]{.smallcaps} trial also reported myocardial infarction as a cardiac endpoint[@b59-co15_s1p016].

In the combined analysis and in the [hera]{.smallcaps} trial, the criteria for withholding or discontinuing trastuzumab are similar; however, [hera]{.smallcaps} uses a lower [lvef]{.smallcaps} cut-off of less than an absolute value of 45% (rather than 50%, as in the combined analysis). In [nsabp]{.smallcaps} B-31, [ncctg]{.smallcaps} N9831, [hera]{.smallcaps}, and [bcirg]{.smallcaps} 006, an absolute difference of more than 4% in the incidence of cardiac death or severe [chf]{.smallcaps} between the trastuzumab group and the observation group would have provoked early discontinuation of the study[@b62-co15_s1p016]. This circumstance did not occur in any of the trials.

3.3 Cardiac Risk in Trastuzumab Adjuvant Trials
-----------------------------------------------

In the trastuzumab adjuvant trials, the use of adjuvant trastuzumab was associated with an absolute increase in the risk of symptomatic [chf]{.smallcaps} of between 0.6% and 3.8% ([Table IV](#tIV-co15_s1p016){ref-type="table"})[@b30-co15_s1p016],[@b57-co15_s1p016]--[@b60-co15_s1p016],[@b66-co15_s1p016]. In the combined analysis of the [nsabp]{.smallcaps} B-31 and [ncctg]{.smallcaps} N9831 trials, 14.2% of patients (164 of 1159) had asymptomatic reductions in [lvef]{.smallcaps} before the planned completion of 52 weeks of trastuzumab therapy[@b65-co15_s1p016]. In the [nsabp]{.smallcaps} B-31 trial, 133 of 714 patients (19%) in the trastuzumab arm had to discontinue trastuzumab for symptomatic (31 patients) or asymptomatic (102 patients) declines in [lvef]{.smallcaps} [@b30-co15_s1p016].

In the [hera]{.smallcaps} trial, 72 participants (4.3%) discontinued trastuzumab because of cardiac problems[@b58-co15_s1p016]. As compared with the [nsabp]{.smallcaps} B-31 and [ncctg]{.smallcaps} N9831 trials, the [hera]{.smallcaps} trial also reported a lower incidence of severe [chf]{.smallcaps} in the trastuzumab group (0.6% vs. 3.8% and 3.5% respectively)[@b58-co15_s1p016]. It has been hypothesized that these differences can be attributed to the sequential rather than concurrent use of trastuzumab with chemotherapy, the longer time interval between completion of chemotherapy and initiation of trastuzumab administration (3 months on average in the [hera]{.smallcaps} trial), and the higher [lvef]{.smallcaps} required as inclusion criteria in the [hera]{.smallcaps} trial (above 55% as compared with above 50% in the combined analysis)[@b58-co15_s1p016].

The [bcirg]{.smallcaps} 006 trial reported a significant difference in symptomatic cardiac events between the [ac]{.smallcaps}/docetaxel group and the [ac]{.smallcaps}/docetaxel/trastuzumab group[@b61-co15_s1p016]. However, no statistically significant difference in cardiac events was observed between the [ac]{.smallcaps}/docetaxel arm and the docetaxel/carboplatin/trastuzumab arm[@b61-co15_s1p016]. Also, at 23 months' follow-up, no statistically significant difference in [dfs]{.smallcaps} was observed between the [ac]{.smallcaps}/docetaxel/trastuzumab (anthracycline-containing) arm and the docetaxel/carboplatin/trastuzumab (non-anthracycline-containing) arm (hazard ratios of 0.49 and 0.61 respectively)[@b61-co15_s1p016], suggesting that non-anthracycline/trastuzumab--containing regimens may be as effective as anthracycline/trastuzumab--containing regimens, with a lower rate of cardiac toxicity.

The only trial that reported no increased risk of cardiac toxicity in the trastuzumab group was Fin[her]{.smallcaps}. Surprisingly, an increased risk of symptomatic and asymptomatic heart failure was observed in the non-trastuzumab arm (statistical significance not reported)[@b59-co15_s1p016]. The major differences in this trial were the smaller study population (*n* = 232) and the duration of trastuzumab therapy (9 weeks).

### 3.3.1 Risk Factors for Trastuzumab-Induced Cardiotoxicity

The risk factors for trastuzumab-induced cardiotoxicity have not been clearly defined. The [nsabp]{.smallcaps} B-31 trial reported increased age (*p* = 0.03), baseline [lvef]{.smallcaps} of 50%--54% (*p* = 0.0003), and post-anthracycline [lvef]{.smallcaps} of 50%--54% (*p* \< 0.0001) as significant risk factors[@b30-co15_s1p016]. Interestingly, this study also showed a suggestion of increased risk with the use of antihypertensive medications before study entry (*p* = 0.02)[@b30-co15_s1p016]. Of note, left-sided radiation, cardiac arrhythmias, and other cardiac risk factors were not found to be risk factors for cardiac toxicity in [nsabp]{.smallcaps} B-31 or [ncctg]{.smallcaps} N98312[@b30-co15_s1p016],[@b66-co15_s1p016]. In the [hera]{.smallcaps} trial, a higher cumulative dose of doxorubicin (287 mg/m^2^ vs. 257 mg/m^2^) or epirubicin (480 mg/m^2^ vs. 422 mg/m^2^), a lower screening [lvef]{.smallcaps}, and a higher body mass index were all associated with trastuzumab-associated cardiac dysfunction[@b67-co15_s1p016]. The other trials have not yet reported analyses of the predictive factors of trastuzumab-induced cardiac dysfunction.

### 3.3.2 Pathogenesis

Little is known about the mechanism of trastuzumab-induced cardiac dysfunction. The transmembrane tyrosine kinase receptor [her]{.smallcaps}2 (ErbB2) promotes cell proliferation when activated[@b51-co15_s1p016]. To study the role of ErbB2 signalling in cardiac tissue, mice with a cardiac-restricted deletion of *ERBB2* were bred[@b68-co15_s1p016],[@b69-co15_s1p016]. The mice were viable and displayed no overt deficits at birth. Over time, the ErbB2-deficient mice were found to develop features of dilated cardiomyopathy, including chamber dilation, wall thinning, and decreased contractility[@b68-co15_s1p016],[@b69-co15_s1p016]. They were also found to be more susceptible to anthracycline-induced cardiac dysfunction[@b68-co15_s1p016]. As a result, the authors suggested that ErbB2 signalling might have a role in myocytes in the prevention of dilated cardiomyopathy triggered by environmental stressors[@b68-co15_s1p016],[@b69-co15_s1p016].

In contrast to anthracycline cardiac toxicity, which is irreversible, dose-dependent, and associated with ultrastructural changes (irreversible myofibril loss, necrosis, and vacuolar degeneration)[@b14-co15_s1p016], trastuzumab-associated cardiac toxicity is thought to be reversible, idiosyncratic, and not associated with structural damage. In a series investigated by the M.D. Anderson Cancer Center, 9 of 38 patients with cardiac toxicity underwent right ventricular endomyocardial biopsies; no ultrastructural changes were seen[@b70-co15_s1p016]. This lack of ultrastructural damage may explain the reversible nature of trastuzumab-related cardiotoxicity as observed in clinical studies (Perez EA, Suman VJ, Davidson N, *et al.* Advances in monoclonal therapy for breast cancer: further analysis of [ncctg]{.smallcaps} N9831. Presented at the 41st Annual Meeting of the American Society of Clinical Oncology; May 16, 2005; Orlando, FL).

### 3.3.3 Reversibility of Trastuzumab-Induced Heart Failure

A retrospective review of 38 patients with trastuzumab-induced cardiotoxicity at M.D. Anderson revealed that the cardiotoxicity might be reversible[@b70-co15_s1p016]. Trastuzumab was discontinued in 37 of these patients, and 31 received standard heart failure treatment, which included both beta-blockers and angiotensin converting-enzyme inhibitors[@b70-co15_s1p016]. All 37 patients showed improvement in [lvef]{.smallcaps} at 1--3 months. Two patients had persistent left ventricular dysfunction at 6 months[@b70-co15_s1p016]. Of the 37 patients, 25 (66%) were rechallenged with trastuzumab (once stability or improvement of left ventricular dysfunction occurred), and only 3 (12%) developed recurrent left ventricular dysfunction or symptoms of [chf]{.smallcaps} (or both) prompting discontinuation of further trastuzumab[@b70-co15_s1p016]. These results provided the first suggestion that it may be safe to reintroduce trastuzumab in patients who develop cardiac dysfunction, once their symptoms or ejection fraction improve with medical therapy.

In the [nsabp]{.smallcaps} B-31 trial, of the 31 patients in the trastuzumab group who met criteria for symptomatic [chf]{.smallcaps} 6 months after the onset of heart failure, 26 were asymptomatic, 1 demonstrated ongoing symptoms of [chf]{.smallcaps}, and 18 remained on cardiac medications[@b64-co15_s1p016]. At 6 months after discontinuation of trastuzumab for either symptomatic [chf]{.smallcaps} or asymptomatic decline in [lvef]{.smallcaps}, 25% of patients continued to show a [lvef]{.smallcaps} below 50%[@b30-co15_s1p016]. Data from [ncctg]{.smallcaps} N9831 and [bcirg]{.smallcaps} 006 are also consistent with this persistent decline in [lvef]{.smallcaps} after discontinuation of trastuzumab. Of the 14 patients who had a cardiac event in the [ncctg]{.smallcaps} N9831 trial, 29% continued to show a [lvef]{.smallcaps} below 50%[@b67-co15_s1p016]. In the [bcirg]{.smallcaps} 006 trial, 180 of 1040 participants (17.3%) treated with [ac]{.smallcaps}, paclitaxel, and trastuzumab had a more than 10% reduction in [lvef]{.smallcaps} relative to baseline. At 42 days, 26% of the participants (37 of 145) had a persistent decline in [lvef]{.smallcaps} on repeat measurement [@b61-co15_s1p016]. These results led to the recognition that, although most patients recover contractility, a significant proportion of patients (approximately 25% in the trials already mentioned) experience persistent contractile dysfunction. Moreover, the long-term implications of trastuzumab-associated [lvef]{.smallcaps} decline---even in patients who subsequently recover to baseline [lvef]{.smallcaps}---are unknown.

3.4 Weighing the Risks and Benefits of Trastuzumab
--------------------------------------------------

Ultimately, the risks and benefits of using trastuzumab must be weighed for patients on an individual basis, taking into account the exclusion criteria used in the adjuvant trials and the risk factors mentioned earlier. Many questions remain unanswered: sequential versus concurrent use of trastuzumab, the necessity of anthracyclines, the long-term significance of asymptomatic declines in [lvef]{.smallcaps}, and the exact pathogenesis and risk factors associated with trastuzumab-induced cardiotoxicity. Also, to date, cardiac toxicity has been evaluated based on systolic function. Little is known about possible diastolic dysfunction associated with trastuzumab.

The [ncctg]{.smallcaps} N9831 trial found a slightly decreased incidence of [chf]{.smallcaps} with sequential rather than concurrent use of trastuzumab with chemotherapy (2.5% vs. 3.5%)[@b62-co15_s1p016]. However, initial reports have suggested that, as compared with concurrent administration, sequential administration of trastuzumab may be less efficacious at preventing breast cancer recurrence (Perez EA, Suman VJ, Davidson N, *et al.* Advances in monoclonal therapy for breast cancer: further analysis of [ncctg]{.smallcaps} N9831. Presented at the 41st Annual Meeting of the American Society of Clinical Oncology; May 16, 2005; Orlando, FL). Nevertheless, the fundamental message of the five trials is unmistakably clear: trastuzumab, regardless of strategy of administration, clearly has an important role in reducing the risk of recurrence of [her]{.smallcaps}2-positive breast cancer. The challenge for the next generation of clinical studies is therefore to find the means of delivering trastuzumab in the most efficacious and least cardiotoxic manner.

Currently, the challenge for clinicians deciding between sequential and concurrent treatment is to balance their patients' cardiac risk with the risk of tumour recurrence and to discuss this balance with their patients---especially when the likelihood of benefit may be low for some patients. With this in mind, the intriguing results of [bcirg]{.smallcaps} 006 raise the question of whether anthracyclines, with their attendant risk of cardiac dysfunction, can be omitted in the management of [her]{.smallcaps}2-positive breast cancer, particularly for patients at high risk of trastuzumab cardiotoxicity[@b61-co15_s1p016]. This question is significant, given that 6.7% of patients who completed doxorubicin and cyclophosphamide therapy in [nsabp]{.smallcaps} B-31 and [ncctg]{.smallcaps} N9831 were not able to initiate trastuzumab therapy because of a decline in [lvef]{.smallcaps} after receiving anthracyclines[@b64-co15_s1p016]. The question of the clinical significance and long-term outcome of asymptomatic decline in [lvef]{.smallcaps} also remains. Longer follow-up in all of the adjuvant trials is needed to assess the implications of the asymptomatic [lvef]{.smallcaps} declines seen in [nsabp]{.smallcaps} B-31, [ncctg]{.smallcaps} N9831, [hera]{.smallcaps}, and [bcirg]{.smallcaps} 006. Until then, the balancing act will continue.

4. AROMATASE INHIBITORS
=======================

Aromatase inhibitors are used in postmenopausal women with hormone receptor--positive breast cancer. They act by inhibiting aromatase, the enzyme responsible for converting androgens to estrogens, thereby reducing estrogen levels. Unlike tamoxifen, [ai]{.smallcaps}s are not partial estrogen agonists. Tamoxifen acts as a selective estrogen receptor modulator at the estrogen receptor. Because tamoxifen is a partial estrogen agonist, it is associated with an increased risk of thromboembolic events and uterine cancer, and it protects against bone demineralization. Aromatase inhibitors are not used alone in premenopausal women, because they cause a reduction in negative feedback on the hypothalamic--pituitary axis and thereby stimulate gonadotropin secretion, which stimulates the ovaries to produce more androgens, ultimately increasing estrogen levels[@b71-co15_s1p016].

As compared with tamoxifen, third-generation [ai]{.smallcaps}s have been shown to improve [dfs]{.smallcaps} in early breast cancer. They can be given as first-line hormonal therapy[@b72-co15_s1p016],[@b73-co15_s1p016], after 2--3 years of treatment with tamoxifen (switching to an [ai]{.smallcaps} rather than completing 5 years with tamoxifen)[@b74-co15_s1p016]--[@b76-co15_s1p016], or as extended treatment following completion of 5 years of tamoxifen[@b77-co15_s1p016]. The switch strategy has also been associated with an over-all survival benefit in [her]{.smallcaps}2-positive patients[@b75-co15_s1p016].

4.1 AIs and Cardiac Toxicity
----------------------------

### 4.1.1 First-line Hormonal Therapy Trials

The Breast International Group ([big]{.smallcaps}) 1--98 trial is a four-arm trial of letrozole as compared with tamoxifen for 5 years. The two additional arms were established to evaluate the early-switch strategy to tamoxifen from letrozole or to letrozole from tamoxifen. So far, only the results of upfront letrozole alone as compared with tamoxifen alone have been reported.

Patients on letrozole experienced improved [dfs]{.smallcaps}, but overall survival did not differ significantly between groups ([Table V](#tV-co15_s1p016){ref-type="table"})[@b74-co15_s1p016],[@b76-co15_s1p016]--[@b80-co15_s1p016]. The rate of all adverse cardiac events was 4.8% in the letrozole group and 4.7% in the tamoxifen group (*p* = 0.87)[@b78-co15_s1p016]. Concerns arose when it was noted that, as compared with women in the tamoxifen arm, women in the letrozole arm had significantly more grades 3, 4, and 5 cardiac events (based on the Common Toxicity Criteria, version 2, of the U.S. National Cancer Institute: 2.4% vs. 1.21%, *p* = 0.001)[@b78-co15_s1p016]. These data must be interpreted with caution because baseline cardiovascular disease, [lvef]{.smallcaps}, and cardiac risk factors were not reported. The letrozole group also experienced a lesser improvement in cholesterol profile than did the tamoxifen group[@b78-co15_s1p016]. The Arimidex, Tamoxifen Alone or in Combination trial also found a statistically significant improvement in [dfs]{.smallcaps} with anastrozole (Arimidex: AstraZeneca Pharmaceuticals, Wilmington, DE, U.S.A.) as compared with tamoxifen[@b79-co15_s1p016]. That study detected no significant difference in the rates of ischemic cardiovascular disease between groups[@b79-co15_s1p016].

### 4.1.2 Switching to an AI After 2--3 Years of Tamoxifen Versus 5 Years of Tamoxifen

The Intergroup Exemestane Study ([ies]{.smallcaps}), a combined analysis of the Austrian Breast and Colorectal Cancer Study Group ([abcsg]{.smallcaps}) 8 study and the Arimidex--Nolvadex ([arno]{.smallcaps})--95 trial, and the Italian Tamoxifen Anastrozole ([ita]{.smallcaps}) trial all compared tamoxifen alone for 5 years with 2--3 years of tamoxifen followed by an [ai]{.smallcaps} to reach a full 5 years of hormonal therapy. The switch to an [ai]{.smallcaps} was associated with a significantly longer [dfs]{.smallcaps} in all of those trials[@b74-co15_s1p016],[@b76-co15_s1p016],[@b80-co15_s1p016]. In the [ies]{.smallcaps} trial, a trend towards increased cardiac events with exemestane as compared with tamoxifen was noted[@b80-co15_s1p016]. None of the trials found a statistically significant difference in cardiac events between the [ai]{.smallcaps} and tamoxifen groups[@b74-co15_s1p016],[@b76-co15_s1p016]. In the [ita]{.smallcaps} trial, a greater rate of lipid metabolism disorders (not defined in the publication from that study) was seen in the anastrozole arm (8.1% vs. 1.4% in the tamoxifen group, *p* = 0.01). No comparison to baseline lipid profiles was reported. Notably, the [ies]{.smallcaps} trial and the combined analysis of [abcsg]{.smallcaps}-8 and [arno]{.smallcaps}-95 excluded patients with a "clinically significant cardiac disorder" or "uncompensated cardiac insufficiency"[@b74-co15_s1p016],[@b75-co15_s1p016]. However, without clear reporting of baseline cardiovascular risk factors, it is difficult to know how to apply the results of these safety analyses to patients with an elevated risk of cardiovascular disease.

### 4.1.3 Extended Treatment with AIs After Completion of 5 Years of Tamoxifen

The [ma]{.smallcaps}.17 trial reported no significant difference in its [ai]{.smallcaps} and placebo arms with regard to the rate of cardiovascular events after 5 years of tamoxifen[@b77-co15_s1p016]. The rates of hypercholesterolemia were 11.9% in the letrozole group and 11.5% in the placebo group (*p* = 0.67)[@b77-co15_s1p016]. This trial reported previous diagnoses of cardiovascular disease at baseline, and rates of cardiovascular disease were comparable in both groups (letrozole: 12%; placebo: 11%). Notably, the [ma]{.smallcaps}.17 trial is the only trial that compared an [ai]{.smallcaps} to placebo rather than to tamoxifen, providing a clearer assessment of the cardiac safety of [ai]{.smallcaps}s. However, given that all of the patients had previously been treated with tamoxifen for 5 years, it is difficult to determine the protective effect that that treatment may or may not have had, and how to interpret the data for patients who will be treated with 5 years of [ai]{.smallcaps} therapy up front, without tamoxifen.

4.2 Are AIs Cardiotoxic?
------------------------

Based on the foregoing data, [ai]{.smallcaps}s appear to be associated with a slightly greater incidence of cardiovascular endpoints; however, such comparisons are not statistically significant in most of the adjuvant [ai]{.smallcaps} trials. Nevertheless, it must be remembered that these trials were not designed to address the issue of cardiac disease. By in large, they did not clearly define criteria for cardiac endpoints or prospective evaluation of cardiac safety[@b81-co15_s1p016]. In addition, clinical follow-up from these trials is currently short, and longer follow-up is required to determine the true cardiac safety of [ai]{.smallcaps}s in the long term.

5. SUMMARY
==========

The advances made in adjuvant systemic therapy have been very successful in reducing the mortality rate associated with breast cancer. More women are now living with breast cancer and more patients are also now receiving a combination of therapies: chemotherapy, targeted therapy, and endocrine treatments. Therefore, addressing the long-term toxicity of treatments is critical.

The present article has highlighted cardiac toxicity as one of the key long-term toxicities of adjuvant systemic therapy. It is important for all practitioners to recognize this toxicity and to make an attempt to reduce its onset by selecting appropriate patients for adjuvant therapy, by selecting appropriate therapy based on patient factors and risk of recurrence, and by increasing awareness and education in patients and allied health care staff about cardiac toxicity. Although optimizing adjuvant therapy to reduce the risk of breast cancer recurrence is critical, recognizing and managing related toxicity is also important.

###### 

Risk factors and strategies to prevent anthracycline-induced cardiotoxicity

  Risk factors                    Prevention strategies
  ------------------------------- ------------------------------------------
  Cumulative anthracycline dose   Alternative anthracyclines
  Increased age                   Liposomal formulations
  Mediastinal radiation           Weekly administration
  Pre-existing cardiac disease    Prolonged infusion
  Hypertension                    Adjunctive dexrazoxane
  Liver disease                   ? Adjunctive beta-blockers or
  Female sex                      Angiotensin converting-enzyme inhibitors

###### 

Clinical trial design and efficacy results for trials of adjuvant trastuzumab in early-stage breast cancer

  Trial                                                                                       Regimen                                                     Patients (*n*)                            Median follow-up (months)   [dfs]{.smallcaps} (%)   [hr]{.smallcaps} (95% [ci]{.smallcaps}/*p* value)                             Overall survival (%)   [hr]{.smallcaps} (95% [ci]{.smallcaps}/*p* value)
  ------------------------------------------------------------------------------------------- ----------------------------------------------------------- ----------------------------------------- --------------------------- ----------------------- ----------------------------------------------------------------------------- ---------------------- ----------------------------------------------------------------------------
  Combined analysis ([nsabp]{.smallcaps} B-31, [ncctg]{.smallcaps} N9831)[@b57-co15_s1p016]   [ac]{.smallcaps}→paclitaxel                                 1989                                      36                          73.1                    0.48 (0.41 to 0.57/\<0.00001)                                                 89.4                   0.65 (0.51 to 0.84/0.0007)
                                                                                              [ac]{.smallcaps}→paclitaxel plus trastuzumab for 1 year     1979                                                                  85.9                                                                                                  92.6                   
  [ncctg]{.smallcaps} N9831                                                                   [ac]{.smallcaps}→paclitaxel→trastuzumab                     985                                                                                                                                                                                                
  [hera]{.smallcaps}[@b56-co15_s1p016],[@b58-co15_s1p016]                                     Chemotherapy→observation                                    1698                                      23.5                        74.3                    0.64 (0.54 to 0.76/\<0.0001)                                                  89.7                   0.66 (0.47 to 0.91/0.0115)
                                                                                              Chemotherapy→trastuzumab for 1 year                         1703                                                                  80.6                                                                                                  92.4                   
                                                                                              Chemotherapy→trastuzumab for 2 years                        1701                                                                                                                                                                                               
  [bcirg]{.smallcaps} 006[@b60-co15_s1p016],[@b61-co15_s1p016]                                [ac]{.smallcaps}→docetaxel                                  1073                                      36                          77                                                                                                    86                     
                                                                                              [ac]{.smallcaps}→docetaxel plus trastuzumab for 1 year      1074                                                                  83                      0.61 (0.48 to 0.76/\<0.0001 compared with [ac]{.smallcaps}→docetaxel group)   92                     0.59 (0.42 to 0.85/0.004 compared with [ac]{.smallcaps}→docetaxel group)
                                                                                              Docetaxel plus carboplatin plus trastuzumab for 1 year      1075                                                                  82                      0.67 (0.54 to 0.83/0.0003 compared with [ac]{.smallcaps}→docetaxel group)     91                     0.66 (0.47 to 0.93/\<0.017 compared with [ac]{.smallcaps}→docetaxel group)
  Fin[her]{.smallcaps}[@b59-co15_s1p016]                                                      Docetaxel→[fec]{.smallcaps}                                 58                                        35                          77.6                                                                                                  89.7                   
                                                                                              Vinorelbine→[fec]{.smallcaps}                               58                                                                                                                                                                                                 
                                                                                              Docetaxel plus trastuzumab (9 weeks) →[fec]{.smallcaps}     54                                        37                          89.3                    0.42 (0.21 to 0.83/0.01)                                                      96.3                   0.41 (0.16 to 1.08/0.07)
                                                                                              Vinorelbine plus trastuzumab (9 weeks) →[fec]{.smallcaps}   62 ([her]{.smallcaps}2-positive subset)                                                                                                                                                            

[dfs]{.smallcaps} = disease-free survival; [hr]{.smallcaps} = hazard ratio; [ci]{.smallcaps} = confidence interval; [nsabp]{.smallcaps} = National Surgical Adjuvant Breast and Bowel Project; [ncctg]{.smallcaps} = North Central Cancer Treatment Group; [ac]{.smallcaps} = doxorubicin, cyclophosphamide; [fec]{.smallcaps} = fluorouracil, epirubicin, cyclophosphamide.

###### 

Cardiac criteria for trials of adjuvant trastuzumab in early-stage breast cancer

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                        [nsabp]{.smallcaps} B-31[@b30-co15_s1p016],[@b64-co15_s1p016]                                                                                                                                                                                                                                                                         [ncctg]{.smallcaps} N9831[@b64-co15_s1p016]                                                                                                                                                                                                                                                                                      [hera]{.smallcaps}[@b56-co15_s1p016],[@b58-co15_s1p016]                                                                                                                                                                                           [bcirg]{.smallcaps} 006[@b60-co15_s1p016],[@b61-co15_s1p016]                                                                                                      Fin[her]{.smallcaps}[@b59-co15_s1p016]
  ------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Cardiac exclusion criteria            [lvef]{.smallcaps} \< [lln]{.smallcaps}\                                                                                                                                                                                                                                                                                              [lvef]{.smallcaps} \< [lln]{.smallcaps}\                                                                                                                                                                                                                                                                                         [lvef]{.smallcaps} \< 55% by echocardiography or [muga]{.smallcaps} after all chemotherapy and radiotherapy\                                                                                                                                      Full description not yet published\                                                                                                                               Age \> 66 years\
                                        History of angina pectoris requiring anti-angina medicationarrhythmias requiring medicationsevere conduction abnormalityclinically significant valvular diseasecardiomegaly on chest radiographpoorly controlled hypertension[mi]{.smallcaps}, [chf]{.smallcaps}, or cardiomyopathyleft ventricular hypertrophy on echocardiography   History of angina pectoris requiring anti-angina medicationarrhythmias requiring medicationsevere conduction abnormalityclinically significant valvular diseasecardiomegaly on chest radiographPoorly controlled hypertension[mi]{.smallcaps}, [chf]{.smallcaps}, or cardiomyopathyclinically significant pericardial effusion   History of documented [chf]{.smallcaps}[cad]{.smallcaps} with previous Q-wave [mi]{.smallcaps}angina pectoris requiring medicationuncontrolled hypertensionclinically significant valvular diseaseunstable angina                                 Approximately, age \> 70 years[lvef]{.smallcaps} \< 50% at baseline                                                                                               Severe hypertension Cardiac disease, including heart failure of any degreearrhythmia requiringregular medication[mi]{.smallcaps} in the last 12 months

  Cardiac monitoring                    Assessment of [lvef]{.smallcaps} with [muga]{.smallcaps} before randomization and at 3, 6, 9, 18 months after randomization                                                                                                                                                                                                           Assessment of [lvef]{.smallcaps} with [muga]{.smallcaps} or echocardiography before randomization and at 3, 6, 9, 18 months after randomization                                                                                                                                                                                  Responses to a cardiac questionnaire, physical exam, 12-lead [ecg]{.smallcaps}, and assessment of [lvef]{.smallcaps} with [muga]{.smallcaps} or echocardiography at baseline, and at 3, 6, 12, 18, 24, 30, 36, 60 months after randomization      Similar to [nsabp]{.smallcaps} B-31                                                                                                                               Assessment of [lvef]{.smallcaps} with [muga]{.smallcaps} or echocardiography at baseline, after the last [fec]{.smallcaps} cycle, and 12 and 36 months after chemotherapy

  Cardiac endpoint definitions          Definitive or probable cardiac death\                                                                                                                                                                                                                                                                                                 Definitive or probable cardiac death\                                                                                                                                                                                                                                                                                            Cardiac death\                                                                                                                                                                                                                                    Definitive or probable cardiac death\                                                                                                                             Cardiac death\
                                        Heart failure with [nyha]{.smallcaps} class [iii]{.smallcaps}/[iv]{.smallcaps} symptoms                                                                                                                                                                                                                                               Heart failure with [nyha]{.smallcaps} class [iii]{.smallcaps}/[iv]{.smallcaps} symptoms\                                                                                                                                                                                                                                         Severe [chf]{.smallcaps} defined as [nyha]{.smallcaps} class [iii]{.smallcaps} or [iv]{.smallcaps} (functional class confirmed by a cardiologist) **and** a decrease in [lvef]{.smallcaps} of at least 10% below baseline and to less than 50%\   Symptomatic [chf]{.smallcaps}\                                                                                                                                    Symptomatic [chf]{.smallcaps}
                                                                                                                                                                                                                                                                                                                                                                              Asymptomatic ([nyha]{.smallcaps} class [i]{.smallcaps}) or mildly symptomatic ([nyha]{.smallcaps} class [ii]{.smallcaps}) with declines in [lvef]{.smallcaps} of 10% or more from baseline to a level of 50% or less                                                                                                             Grade 3 or 4 ischemia/infarction\                                                                                                                                                                                                                 [mi]{.smallcaps}\                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Grade 3 or 4 arrhythmias\                                                                                                                                                                                                                         Asymptomatic decline in [lvef]{.smallcaps} of more than 15% from baseline or of more than 10% from baseline resulting in an [lvef]{.smallcaps} of less than 50%   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Asymptomatic [lvef]{.smallcaps} decline, defined as an absolute [lvef]{.smallcaps} decline of more than 15% or [lvef]{.smallcaps} below the lower limit of normal                                                                                                                                                                                                                                                   

  Criteria to hold trastuzumab          Asymptomatic decline in [lvef]{.smallcaps} of more than 15% or to below the [lln]{.smallcaps}                                                                                                                                                                                                                                         Asymptomatic decline in [lvef]{.smallcaps} of more than 15% or to below the [lln]{.smallcaps}                                                                                                                                                                                                                                    Asymptomatic, and [lvef]{.smallcaps} of 45% or lower or [lvef]{.smallcaps} of 50% or lower and declined by at least 10% from baseline                                                                                                             Similar to [nsabp]{.smallcaps} B-31                                                                                                                               Not reported

  Criteria to discontinue trastuzumab   Symptomatic cardiac dysfunction while receiving trastuzumab\                                                                                                                                                                                                                                                                          Symptomatic cardiac dysfunction while receiving trastuzumab\                                                                                                                                                                                                                                                                     Symptomatic heart failure **and** [lvef]{.smallcaps} \< 45% or [lvef]{.smallcaps} \< 50% and declined by at least 10% from baseline\                                                                                                              Similar to [nsabp]{.smallcaps} B-31                                                                                                                               Not reported
                                        In asymptomatic patients, [lvef]{.smallcaps} fails to recover to above [lln]{.smallcaps} after trastuzumab held for 4 weeks                                                                                                                                                                                                           In asymptomatic patients, [lvef]{.smallcaps} fails to recover to above [lln]{.smallcaps} after trastuzumab held for 4 weeks                                                                                                                                                                                                      Asymptomatic patients whose [lvef]{.smallcaps} fails to recover after trastuzumab held for 3 weeks\                                                                                                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Patients in whom trastuzumab was re-introduced and who subsequently experienced another decline in [lvef]{.smallcaps}                                                                                                                                                                                                                                                                                               
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

[nsabp]{.smallcaps} = National Surgical Adjuvant Breast and Bowel Project; [ncctg]{.smallcaps} = North Central Cancer Treatment Group; [hera]{.smallcaps} = Herceptin Adjuvant (Trial); [bcirg]{.smallcaps} = Breast Cancer International Research Group; Fin[her]{.smallcaps} = Finland Herceptin (Trial); [lvef]{.smallcaps} = left ventricular ejection fraction; [lln]{.smallcaps} = lower limit of normal (assumed to be 50%); [mi]{.smallcaps} = myocardial infarction; [chf]{.smallcaps} = congestive heart failure; [muga]{.smallcaps} = multiple gated acquisition; [cad]{.smallcaps} = coronary artery disease; [ecg]{.smallcaps} = electrocardiograph; [fec]{.smallcaps} = fluorouracil, epirubicin, cyclophosphamide; [nyha]{.smallcaps} = New York Heart Association.

###### 

Cardiac toxicity in the trials of adjuvant trastuzumab in early-stage breast cancer

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Trial                                                            Regimen                                                    Patients (*n*)   Follow-up (months)   Cardiac death (%)   Severe [chf]{.smallcaps}--- [nyha iii]{.smallcaps}/[iv]{.smallcaps} (%)   Symptomatic [chf]{.smallcaps}, including severe (%)   Decrease in [lvef]{.smallcaps} by 15% or more from baseline (%)   Discontinued trastuzumab because of cardiac problems (%)
  ---------------------------------------------------------------- ---------------------------------------------------------- ---------------- -------------------- ------------------- ------------------------------------------------------------------------- ----------------------------------------------------- ----------------------------------------------------------------- ----------------------------------------------------------
  [nsabp]{.smallcaps} B-31[@b57-co15_s1p016],[@b64-co15_s1p016]    [ac]{.smallcaps}→paclitaxel                                814              60 \[36\]            0.1 (*n*=1)         0.9                                                                       \[1\]                                                 [nr]{.smallcaps}                                                  [na]{.smallcaps}

                                                                   [ac]{.smallcaps}→paclitaxel plus trastuzumab for 1 year    850                                   0.0                 3.8                                                                       \[5.1\]                                               \[14\]                                                            \[19\]

  [ncctg]{.smallcaps} N9831[@b57-co15_s1p016],[@b66-co15_s1p016]   [ac]{.smallcaps}→paclitaxel                                                 36                   0.1 (*n*=1)         0.3                                                                       [nr]{.smallcaps}                                      6.7                                                               [na]{.smallcaps}

                                                                   [ac]{.smallcaps}→paclitaxel plus trastuzumab for 1 year                                          0.0                 3.5                                                                                                                             17.3                                                              15.4

                                                                   [ac]{.smallcaps}→paclitaxel→ trastuzumab                                                                             2.5                                                                                                                                                                                               

  [hera]{.smallcaps}[@b58-co15_s1p016]                             Chemotherapy → observation                                 1708             24                   0.06 (*n*=1)        0.00                                                                      0.12                                                  2.1[a](#tfn3-co15_s1p016){ref-type="table-fn"}                    [na]{.smallcaps}

                                                                   Chemotherapy→ trastuzumab for 1 year                       1678                                  0.00\               0.60\                                                                     2.15\                                                 7.0[a](#tfn3-co15_s1p016){ref-type="table-fn"}                    4.3 *p\<*0.0001
                                                                                                                                                                    *p*=1.0             *p\<*0.0001                                                               *p\<*0.0001                                                                                                             

  [bcirg]{.smallcaps} 006[@b60-co15_s1p016]                        [ac]{.smallcaps}→docetaxel                                 1073             36                   0.0                 0.4                                                                       [na]{.smallcaps}                                      10.1                                                              [na]{.smallcaps}

                                                                   [ac]{.smallcaps}→docetaxel plus trastuzumab for 1 year     1074                                  0.0                 1.9                                                                       18.1                                                  [nr]{.smallcaps}                                                  

                                                                   Docetaxel plus carboplatin plus trastuzumab for 1 year     1075                                  0.0                 0.4                                                                       8.6                                                   [nr]{.smallcaps}                                                  

  Fin[her]{.smallcaps}[@b59-co15_s1p016]                           Docetaxel→[fec]{.smallcaps}                                58               35                   0.0                 2.8                                                                       [na]{.smallcaps}                                      6.0                                                               [na]{.smallcaps}

                                                                   Vinorelbine→[fec]{.smallcaps}                              58                                                        (*n*=4)[b](#tfn4-co15_s1p016){ref-type="table-fn"}                                                                                                                                                

                                                                   Docetaxel plus trastuzumab (9 weeks)→[fec]{.smallcaps}     54                                    0.0                 0.0[b](#tfn4-co15_s1p016){ref-type="table-fn"}                                                                                  3.5                                                               [nr]{.smallcaps}

                                                                   Vinorelbine plus trastuzumab (9 weeks)→[fec]{.smallcaps}   62               37                                                                                                                                                                                                                                         
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Decrease in left ventricular ejection fraction by 10% or more from baseline and below 50%.

Includes infarction and cardiac failure.

[chf]{.smallcaps} = congestive heart failure; [nyha]{.smallcaps} = New York Heart Association class; [lvef]{.smallcaps} = left ventricular ejection fraction; [nsabp]{.smallcaps} = National Surgical Adjuvant Breast and Bowel Project; [ac]{.smallcaps} = doxorubicin, cyclophosphamide; [nr]{.smallcaps} = not reported; [na]{.smallcaps} = not applicable; [ncctg]{.smallcaps} = North Central Cancer Treatment Group; [hera]{.smallcaps} = Herceptin Adjuvant (Trial); [bcirg]{.smallcaps} = Breast Cancer International Research Group; Fin[her]{.smallcaps} = Finland Herceptin (Trial); [fec]{.smallcaps} = fluorouracil, epirubicin, cyclophosphamide.

###### 

Summary of aromatase inhibitor trials: efficacy and cardiac events

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Trial                                                                                  Regimen                            Median follow-up   Approximate [hr]{.smallcaps} for [dfs]{.smallcaps}/[efs]{.smallcaps} (95% [ci]{.smallcaps}/*p* value)   Cardiac events \[% (*p* value)\]
  -------------------------------------------------------------------------------------- ---------------------------------- ------------------ ------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------
  [big]{.smallcaps}-1.98[@b78-co15_s1p016]                                               Letrozole alone\                   51 months          0.82 (0.71 to 0.95/0.007)                                                                               All cardiac events: 2.4 vs. 1.4 (0.001)\
                                                                                         Tamoxifen alone                                                                                                                                               Ischemic heart disease (overall, grades 3--5): 1.1 and 0.7 (0.06)\
                                                                                                                                                                                                                                                       Cardiac failure (overall, grades 3--5): 0.7 and 0.3 (0.04)

  [atac]{.smallcaps}[@b79-co15_s1p016]                                                   Anastrozole alone\                 68 months          0.87 (0.78 to 0.97/0.01)                                                                                Ischemic cardiovascular disease: 4.1 vs. 3.6 (0.1)
                                                                                         Tamoxifen alone                                                                                                                                               

  [ies]{.smallcaps}[@b80-co15_s1p016]                                                    Tamoxifen→exemestane\                                 0.74 (0.64 to 0.85/0.0001)                                                                              Myocardial infarction: 1.3 vs. 0.8\
                                                                                         Tamoxifen alone                                                                                                                                               Angina: 7.1 vs. 6.5

  Combined analysis: [abcsg]{.smallcaps}-8 and [arno]{.smallcaps}-95[@b74-co15_s1p016]   Tamoxifen→anastrozole\             28 months          0.61 (0.42--0.87/0.0009)                                                                                Myocardial infarction: \<1% vs. \<1% (1.0)
                                                                                         Tamoxifen alone                                                                                                                                               

  [ita]{.smallcaps}[@b76-co15_s1p016]                                                    Tamoxifen→anastrozole\             64 months          0.57 (0.38 to 0.85/0.01)                                                                                Cardiovascular disease: 7.6 vs. 6.2 (0.6)
                                                                                         Tamoxifen alone                                                                                                                                               

  [ma]{.smallcaps}.17[@b77-co15_s1p016]                                                  Tamoxifen for 5 years→letrozole\   2.4 years          0.57 (0.43 to 0.75/0.00008)                                                                             Cardiovascular events: 4.1 vs. 3.6 (0.24)
                                                                                         Tamoxifen for 5 year→placebo                                                                                                                                  
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
